

Chee W Ong

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7281712/chee-w-ong-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

860
citations

15
h-index

23
g-index

23
ext. papers

976
ext. citations

9.5
avg, IF

3.19
L-index

#	Paper	IF	Citations
22	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. <i>NAR Cancer</i> , 2020 , 2, zcaa012	5.2	1
21	Genetics of lipid metabolism in prostate cancer. <i>Nature Genetics</i> , 2018 , 50, 169-171	36.3	15
20	A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases. <i>Journal of Pathology: Clinical Research</i> , 2018 , 4, 103-113	5.3	7
19	Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists. <i>Cell Death and Disease</i> , 2018 , 9, 1081	9.8	9
18	EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 230-242	12.9	73
17	PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry. <i>Human Pathology</i> , 2016 , 47, 95-103	3.7	13
16	PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. <i>Oncotarget</i> , 2016 , 7, 7885-98	3.3	25
15	The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers. <i>Oncotarget</i> , 2015 , 6, 12763-73	3.3	14
14	AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 164-75	12.9	83
13	Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population. <i>Clinical and Translational Gastroenterology</i> , 2014 , 5, e51	4.2	29
12	Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. <i>Antioxidants and Redox Signaling</i> , 2014 , 20, 2326-46	8.4	31
11	TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities. <i>Oncotarget</i> , 2014 , 5, 1609-20	3.3	28
10	Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2013 , 368, 2266-76	59.2	166
9	KIT gene mutation analysis in solid tumours: biology, clinical applications and trends in diagnostic reporting. <i>Pathology</i> , 2013 , 45, 127-37	1.6	9
8	Proteomic analysis of colorectal cancer metastasis: stathmin-1 revealed as a player in cancer cell migration and prognostic marker. <i>Journal of Proteome Research</i> , 2012 , 11, 1433-45	5.6	40
7	Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. <i>Gastric Cancer</i> , 2012 , 15, 188-97	7.6	31
6	Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer. <i>Cancer Science</i> , 2011 , 102, 1855-61	6.9	10

5	RUNX3 functions as an oncogene in ovarian cancer. <i>Gynecologic Oncology</i> , 2011 , 122, 410-7	4.9	52
4	Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. <i>EMBO Molecular Medicine</i> , 2011 , 3, 451-64	12	41
3	Computer-assisted pathological immunohistochemistry scoring is more time-effective than conventional scoring, but provides no analytical advantage. <i>Histopathology</i> , 2010 , 56, 523-9	7.3	32
2	CD133 expression predicts for non-response to chemotherapy in colorectal cancer. <i>Modern Pathology</i> , 2010 , 23, 450-7	9.8	133
1	TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery. <i>Pathology</i> , 2008 , 40, 441-9	1.6	18